Transcept (TSPT) Dismisses Action Against Watcon (WPI) Over Generic Intermezzo ANDA
Tweet Send to a FriendGet Alerts TSPT Hot Sheet
Trade TSPT Now!
As previously reported, on July 19, 2012, Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) received a Paragraph IV notice letter from Watson Laboratories, Inc. – Florida (NYSE: WPI), advising Transcept that Watson had filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for generic versions of Intermezzo (zolpidem tartrate) sublingual tablet C-IV. In response to Watson’s ANDA, on August 27, 2012, Transcept joined Purdue Pharma and Purdue Pharma L.P. (collectively, “Purdue”) in filing an action (the “Action”) against Watson, Watson Pharmaceuticals, Inc. and Watson Pharma, Inc.
On November 28, 2012, Watson withdrew its ANDA, and, as a result of such withdrawal, on December 18, 2012 Transcept and Purdue agreed to voluntarily dismiss the Action without prejudice and on December 20, 2012 a court order was entered to such effect. The dismissal of the Action has no effect on the ANDA filed by Actavis Elizabeth LLC, a wholly owned subsidiary of Watson Pharmaceuticals, Inc., which was reported by Transcept on July 19, 2012.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
On November 28, 2012, Watson withdrew its ANDA, and, as a result of such withdrawal, on December 18, 2012 Transcept and Purdue agreed to voluntarily dismiss the Action without prejudice and on December 20, 2012 a court order was entered to such effect. The dismissal of the Action has no effect on the ANDA filed by Actavis Elizabeth LLC, a wholly owned subsidiary of Watson Pharmaceuticals, Inc., which was reported by Transcept on July 19, 2012.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Depomed (DEPO) Reports Submission of ANDA for Generic Zipsor
- Tesla (TSLA) Announces Partial Model S Recall
- Gene Patent Limited by High Court in Mixed Ruling for Myriad (MYGN)
Create E-mail Alert Related Categories
Corporate News, FDA, LitigationLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

Down)